Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:EL
NYSE:ELPersonal Products

Is Estée Lauder (EL) Pricing Reflect A Rebound After Recent Share Price Slide

This article examines whether Estée Lauder Companies is attractively priced after a difficult period in the market, or whether the stock could still face further downside, by focusing on what the current share price might imply about value. The stock last closed at US$69.12, with a 0.9% decline over 7 days, a 30.0% decline over 30 days, a 35.3% decline year to date, a 20.7% gain over 1 year, and declines of 69.7% over 3 years and 75.1% over 5 years. Together, these figures present a mixed...
NYSE:SYK
NYSE:SYKMedical Equipment

Does Stryker’s Cyberattack Recovery Reveal Hidden Strengths in Its Long-Term Thesis (SYK)?

In March 2026, Stryker reported a cyberattack that temporarily disrupted custom implant operations but, by late March, restored its electronic ordering system and most manufacturing capacity while maintaining product safety. With first-quarter 2026 results due on April 30, investors are watching how quickly Stryker’s operations normalize and what the incident reveals about its resilience and risk controls. We’ll now explore how Stryker’s rapid operational recovery from the cyberattack could...
OM:NP3
OM:NP3Real Estate

Assessing NP3 Fastigheter (OM:NP3) Valuation After Preference Share Issue And Key AGM Proposals

NP3 Fastigheter (OM:NP3) is back in focus after a directed issue of preference shares and ahead of an AGM that will vote on dividends, a new incentive programme and fresh share issue authorisations. See our latest analysis for NP3 Fastigheter. Recent capital raising via preference shares and the upcoming AGM decisions appear to be in focus for investors. A 4.18% 7 day share price return contrasts with a 3.11% 1 month share price decline and a 90.28% 5 year total shareholder return, which...
NYSE:HXL
NYSE:HXLAerospace & Defense

Is Hexcel’s Expanded Revolver Reshaping Its Aerospace Investment Case (HXL)?

Hexcel Corporation recently entered into a new US$750 million revolving credit facility maturing in 2031, drawing US$300 million to refinance its prior credit agreement without penalties and securing funds for general corporate uses, including acquisitions and investments. The new facility’s flexible structure, potential for up to US$500 million in additional commitments, and covenant framework reshapes Hexcel’s balance sheet options and risk profile ahead of its upcoming first-quarter 2026...
NYSE:TOST
NYSE:TOSTDiversified Financial

Is Toast (TOST) Pricing Fair After Recent Share Price Weakness And Product Rollouts?

If you are wondering whether Toast's current share price is fair, expensive, or offers value, this article walks through the numbers so you can judge that for yourself. Toast shares last closed at US$26.47, with recent returns of 0.3% over 7 days, a 9.1% decline over 30 days, a 22.2% decline year to date, and a 19.0% decline over 1 year, while the 3 year return stands at 59.9%. Recent coverage has focused on Toast's position in the restaurant technology space and its ability to scale its...
NYSE:COR
NYSE:CORHealthcare

Cencora Expands Retina Network As CFO Retirement Opens New Chapter

Cencora (NYSE:COR) has signed a binding agreement to acquire the retina division of EyeSouth Partners, expanding its Retina Consultants of America network. The transaction centers on advanced retina care services and is intended to deepen Cencora's presence in ophthalmology-focused healthcare offerings. The company also announced the planned retirement of Chief Financial Officer James F. Cleary and has initiated an executive search for his successor. Cencora operates across pharmaceutical...
NasdaqGS:MMYT
NasdaqGS:MMYTHospitality

How Short Seller Claims on Transparency and Regulation Will Impact MakeMyTrip (MMYT) Investors

In late March 2026, activist short seller Morpheus Research released a report alleging that MakeMyTrip violated regulatory bans on price parity clauses and raised questions about accounting practices, including the treatment of a receivable from insolvent airline Go Air. The report also highlighted a large gap between MakeMyTrip’s adjusted profits and IFRS figures, bringing renewed attention to the company’s financial transparency and regulatory exposure. We’ll now explore how these...
NasdaqGM:KALV
NasdaqGM:KALVBiotechs

Why KalVista Pharmaceuticals (KALV) Is Up 5.0% After Promising Pediatric EKTERLY HAE Trial Results – And What's Next

KalVista Pharmaceuticals recently reported new interim results from its KONFIDENT-KID trial, showing that EKTERLY (sebetralstat) oral disintegrating tablets treated 172 hereditary angioedema attacks in 33 children aged 2–11 with rapid symptom relief and no serious or treatment-related adverse events. The data highlight how an easy-to-administer oral option could address a major gap in pediatric hereditary angioedema care, where current on-demand treatment for young patients in the US is...
NasdaqGS:ADBE
NasdaqGS:ADBESoftware

Assessing Adobe’s Valuation After Analyst Downgrades And CEO Retirement Announcement

Analyst downgrades and CEO exit put Adobe’s risk profile in focus Recent downgrades of Adobe (ADBE) and the planned retirement of long-serving CEO Shantanu Narayen have put leadership, pricing power, and AI competition at the center of the stock’s story for investors. Several research houses, including William Blair, have questioned how resilient Adobe’s Creative Cloud economics are as free or low cost design tools and AI native rivals gain traction, even as the company continues to invest...
BIT:REY
BIT:REYIT

Is It Time To Reevaluate Reply (BIT:REY) After Its 44% One Year Share Price Slide?

Wondering whether Reply is starting to look attractively priced after a tough run, or if the current share price still leaves questions on value. Reply shares last closed at €82.05, after a recent 5% gain over 7 days but still showing a 9.1% decline over 30 days and a 26.0% decline year to date, with a 44.0% decline over the past year. These moves have put valuation and risk firmly in focus for investors, especially as longer term performance over 3 and 5 years, at 24.5% and 22.8% declines...
NasdaqGS:CME
NasdaqGS:CMECapital Markets

CME Group’s Record Volumes And 24 7 Push Test Current Valuation

CME Group (NasdaqGS:CME) reports record trading volumes across all product categories. The company launches 24/7 trading for regulated cryptocurrency futures and options. CME partners with BMO and Google Cloud to roll out 24/7 tokenized cash settlement for institutional clients. CME Group, trading at $305.11, is drawing attention after reporting all time record volumes across multiple asset classes and pushing further into round the clock trading. The stock is up 13.1% year to date and...